

# Andrea Lania

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12068791/publications.pdf>

Version: 2024-02-01

33  
papers

1,186  
citations

471509

17  
h-index

477307

29  
g-index

37  
all docs

37  
docs citations

37  
times ranked

1313  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Thyroid Autoimmunity on Assisted Reproductive Technology Outcomes and Ovarian Reserve Markers: An Updated Systematic Review and Meta-Analysis. <i>Thyroid</i> , 2022, 32, 1010-1028.	4.5	7
2	Skeletal health in patients with differentiated thyroid carcinoma. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 431-442.	3.3	15
3	Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study. <i>Endocrine</i> , 2021, 73, 255-260.	2.3	16
4	Thyrotoxicosis in patients with COVID-19: the THYRCOV study. <i>European Journal of Endocrinology</i> , 2020, 183, 381-387.	3.7	262
5	Central Hypothyroidism. , 2019, , 245-253.		0
6	Levothyroxine supplementation on assisted reproduction technology (ART) outcomes in women with subtle hypothyroidism: a retrospective study. <i>Gynecological Endocrinology</i> , 2018, 34, 1053-1058.	1.7	4
7	Central Hypothyroidism. <i>Endocrinology</i> , 2018, , 373-389.	0.1	0
8	Central hypothyroidism â€” a neglected thyroid disorder. <i>Nature Reviews Endocrinology</i> , 2017, 13, 588-598.	9.6	92
9	Expression of protein kinase A regulatory subunits in benign and malignant human thyroid tissues: A systematic review. <i>Experimental Cell Research</i> , 2016, 346, 85-90.	2.6	7
10	Central Hypothyroidism. <i>Endocrinology</i> , 2016, , 1-17.	0.1	0
11	Pituitary incidentalomas. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2012, 26, 395-403.	4.7	12
12	cAMP pathway and pituitary tumorigenesis. <i>Annales D'Endocrinologie</i> , 2012, 73, 73-75.	1.4	9
13	The dopamineâ€™somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways. <i>Cancer Letters</i> , 2010, 288, 170-176.	7.2	49
14	G-Protein and Signalling in Pituitary Tumours. <i>Hormone Research in Paediatrics</i> , 2009, 71, 95-100.	1.8	17
15	Central hypothyroidism. <i>Pituitary</i> , 2008, 11, 181-186.	2.9	75
16	The Third Intracellular Loop of the Human Somatostatin Receptor 5 Is Crucial for Arrestin Binding and Receptor Internalization after Somatostatin Stimulation. <i>Molecular Endocrinology</i> , 2008, 22, 676-688.	3.7	39
17	Molecular Pathogenesis of Pituitary Adenomas. , 2008, , 1-15.		0
18	Hormonal Signaling and Pituitary Adenomas. <i>Neuroendocrinology</i> , 2007, 85, 101-109.	2.5	17

#	ARTICLE	IF	CITATIONS
19	Pathogenesis of Prolactinomas. <i>Pituitary</i> , 2005, 8, 7-15.	2.9	30
20	Expression of the Antiapoptotic Gene Seladin-1 and Octreotide-Induced Apoptosis in Growth Hormone-Secreting and Nonfunctioning Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 6156-6161.	3.6	55
21	Genetics of Pituitary Tumors: Focus on G-Protein Mutations. <i>Experimental Biology and Medicine</i> , 2003, 228, 1004-1017.	2.4	57
22	Growth factors and human pituitary adenomas. <i>Molecular and Cellular Endocrinology</i> , 2002, 197, 63-68.	3.2	11
23	Calcium-sensing receptor expression and signalling in human parathyroid adenomas and primary hyperplasia. <i>Clinical Endocrinology</i> , 2000, 52, 339-348.	2.4	94
24	Induction of Specific Phosphodiesterase Isoforms by Constitutive Activation of the cAMP Pathway in Autonomous Thyroid Adenomas <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2872-2878.	3.6	56
25	Expression of Calcium-Sensing Receptor and Characterization of Intracellular Signaling in Human Pituitary Adenomas <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2848-2853.	3.6	29
26	G protein abnormalities in pituitary adenomas. <i>Molecular and Cellular Endocrinology</i> , 1998, 142, 1-14.	3.2	40
27	Activating Mutations of the Gs $\alpha$ Gene Are Associated with Low Levels of Gs $\alpha$ Protein in Growth Hormone-Secreting Tumors <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 4386-4390.	3.6	47
28	Constitutively Active Gs $\alpha$ Is Associated with an Increased Phosphodiesterase Activity in Human Growth Hormone-Secreting Adenomas <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 1624-1628.	3.6	71
29	Cellular abnormalities in pituitary tumors. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 46-48.	3.4	7
30	Mechanism of Action of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in Human Nonfunctioning Pituitary Tumors. <i>Journal of Neuroendocrinology</i> , 1995, 7, 695-702.	2.6	11
31	Thyrotrophin-Releasing Hormone Raises Cytosolic Free Calcium Concentration in Human Adenomatous Somatotrophs and Corticotrophs; Comparison with in vivo Responsiveness to Thyrotrophin-Releasing Hormone in Patients with Acromegaly or Cushing's Disease. <i>Journal of Neuroendocrinology</i> , 1991, 3, 51-56.	2.6	2
32	Hypothalamic Peptides Modulate Cytosolic Free Ca <sup>2+</sup> Levels and Adenylate Cyclase Activity in Human Nonfunctioning Pituitary Adenomas*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991, 73, 913-918.	3.6	29
33	Inhibition of Basal and Corticotropin-Releasing Hormone-Stimulated Adenylate Cyclase Activity and Cytosolic Ca <sup>2+</sup> Levels by Somatostatin in Human Corticotropin-Secreting Pituitary Adenomas*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990, 70, 1262-1268.	3.6	26